•  
• Tweet
•  
•        Print
•  
•         Track Keywords
•  
• 

Laxman Pai, Opalesque Asia:

European life science venture capital firm Forbion has raised €1.35bn ($1.5 billion) across a pair of new funds, bringing the total of funds under management to €3 billion.

The Netherlands-based firm said in a press release that both funds exceeded their original target sizes and represent Forbion's largest fundraising success to date.

The final close of the Forbion Ventures Fund VI has reached the hard cap amount of €750 million and the final close of the Forbion Growth Opportunities Fund II has also been secured at the hard cap amount of €600 million. The two funds meet the needs of distinct segments of the market.

The Forbion Ventures Fund VI is focused on building companies at an earlier stage of development and the Forbion Growth Opportunities Fund II supports the expansion of late-stage life sciences companies.

Sander Slootweg, Managing Partner and co-founder of Forbion said: "We are extremely proud of the confidence investors have placed in us as evidenced by the €1.35 billion that we have raised. This is a record for Forbion and a testament to our long track record as a leading investor that supports ambitious management teams and successful life sciences companies across different stages of their development."

"Achieving the final close of the Forbion Growth Opportunities Fund II at the hard cap highlights the continuing need for investment in late-stage European life sciences companies, a market......................

To view our full article Click here